ArticleAJNR. American journal of neuroradiology2009
Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?
Article in AJNR. American journal of neuroradiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.AJNR. American journal of neuroradiology · 2015Guideline
- Characterization and therapy monitoring of head and neck carcinomas using diffusion-imaging-based intravoxel incoherent motion parameters-preliminary results.Neuroradiology · 2013Trial
- Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.AJNR. American journal of neuroradiology · 2012Trial
- Article
- Physiological MRI of microvascular architecture, neovascularization activity, and oxygen metabolism facilitate early recurrence detection in patients with IDH-mutant WHO grade 3 glioma.Neuroradiology · 2022Article
- Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis.Current opinion in oncology · 2021Review
- Metabolic Tumor Microenvironment Characterization of Contrast Enhancing Brain Tumors Using Physiologic MRI.Metabolites · 2021Article
- Histogram-based analysis of cerebral blood flow using arterial spin labeling MRI in de novo brain gliomas: relationship to histopathologic grade and molecular markers.Neuroradiology · 2021Article
- Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma.Scientific reports · 2021Article
- Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging.PloS one · 2021Article
- Clinical Validation of Automatable Gaussian Normalized CBV in Brain Tumor Analysis: Superior Reproducibility and Slightly Better Association with Survival than Current Standard Manual Normal Appearing White Matter Normalization.Translational oncology · 2018Article
- Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.Scientific reports · 2018Article
- MR Imaging Features of Anaplastic Pleomorphic Xanthoastrocytoma Mimicking High-Grade Astrocytoma.AJNR. American journal of neuroradiology · 2018Article
- The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies.Current treatment options in oncology · 2018Review
- A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas.NeuroImage. Clinical · 2018Article
- Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.Experimental and therapeutic medicine · 2017Article
- Quantitative measurement of cerebral blood volume using velocity-selective pulse trains.Magnetic resonance in medicine · 2017Article
- Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Neuro-oncology · 2016Article
- 3D Deep Learning for Multi-modal Imaging-Guided Survival Time Prediction of Brain Tumor Patients.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2016Article
- Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.European journal of nuclear medicine and molecular imaging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCurrent classification and grading of primary brain tumors has significant limitations. Our aim was to determine whether the relative cerebral volume (rCBV) measurements in gliomas may serve as an adjunct to histopathologic grading, with a hypothesis that rCBV values are more accurate in predicting 1-year survival and recurrence. MATERIALS AND
methodsThirty-four patients with gliomas (WHO grade I-IV, 27 astrocytomas, 7 tumors with oligodendroglial components) underwent contrast-enhanced MR rCBV measurements before treatment. The region of interest and the single pixel with the maximum CBV value within the tumors were normalized relative to the contralateral normal tissue (rCBV(mean) and rCBV(max), respectively). Karnofsky performance score and progression-free survival (PFS) were recorded. Receiver operating characteristic curves and Kaplan-Meier survival analysis were conducted for CBV and histologic grade (WHO grade).
resultsSignificant correlations were detected only when patients with oligodendrogliomas and oligoastrocytomas were excluded. The rCBV(mean) and rCBV(max) in the astrocytomas were 3.5 +/- 2.9 and 3.7 +/- 2.7. PFS correlated with rCBV parameters (r = -0.54 to -0.56, P < or = .009). WHO grade correlated with rCBV values (r = 0.65, P < or = .0002). rCBV(max) > 4.2 was found to be a significant cutoff value for recurrence prediction with 77.8% sensitivity and 94.4% specificity (P = .0001). rCBV(max) < or = 3.8 was a significant predictor for 1-year survival (93.7% sensitivity, 72.7% specificity, P = .0002). The relative risk for shorter PFS was 11.1 times higher for rCBV(max) > 4.2 (P = .0006) and 6.7 times higher for WHO grade > II (P = .05). The combined CBV-WHO grade classification enhanced the predictive value for recurrence/progression (P < .0001).
conclusionsrCBV values in astrocytomas but not tumors with oligodendroglial components are predictive for recurrence and 1-year survival and may be more accurate than histopathologic grading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.